First Eagle美国股票主动型ETF USFE 深 沪
等待开盘 03-26 09:30:00 美东时间
33.2831
+0.154
+0.46%
华盛通- 最 高33.2831
- 今 开--
- 成交量 0股
- 最 低 33.2831
- 昨 收 33.1292
- 总市值 0
- 52周最高 36.07
- 市盈率 静 --
- 换手率 NaN.00%
- 52周最低 32.8613
- 委 比 0.00%
- 总股本 --
- 历史最高 36.07
- 量 比 0
- 振 幅 0.00%
- 历史最低 32.8613
- 每 手 1
- 风险率 0.89%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多BRIEF-Takeda Pharmaceutical Co Ltd - Takeda Announces U.S. FDA Accepts NDA And Grants Priority Review For Rusfertide As A Potential First-In-Class Therapy For Polycythemia Vera
BRIEF-Takeda Pharmaceutical Co Ltd - Takeda Announces U.S. FDA Accepts NDA And Grants Priority Review For Rusfertide As A Potential First-In-Class Therapy For Polycythemia Vera March 2 (Reuters) - Takeda Pharmaceutical Co Ltd 4502.T : TAKEDA PHARMACEUTICAL CO LTD: TAKEDA ANNOUNCES U.S. FDA ACCEPTS N
03-02 15:02
First Eagle's Active ETF Push Gathers Steam With New US Value Launches
First Eagle expands its active ETF lineup with two new U.S. value funds as ETF AUM hits $1.5 billion, building on strong early momentum.
01-29 04:18
BRIEF-Stem Appoints New Chief Financial Officer
July 2 (Reuters) - Stem Inc STEM.N: STEM APPOINTS NEW CHIEF FINANCIAL OFFICER STEM INC - APPOINTS BRIAN MUSFELDT AS CFO EFFECTIVE JULY 17, 2025 STEM INC - DORAN HOLE STEPS DOWN AS CFO EFFECTIVE JULY 1...
2025-07-03 04:16
BRIEF-Protagonist Therapeutics Takeda To Lead Regulatory Strategy For Rusfertide In Polycythemia Vera NDA
March 20 (Reuters) - Protagonist Therapeutics Inc PTGX.O: PROTAGONIST THERAPEUTICS- TAKEDA TO LEAD REGULATORY STRATEGY FOR RUSFERTIDE IN POLYCYTHEMIA VERA NDA PROTAGONIST THERAPEUTICS INC - TRANSITION...
2025-03-21 04:58
BRIEF-Protagonist And Takeda Announce Positive Topline Results From Phase 3 Verify Study Of Rusfertide
March 3 (Reuters) - Takeda Pharmaceutical 4502.T: PROTAGONIST AND TAKEDA ANNOUNCE POSITIVE TOPLINE RESULTS FROM PHASE 3 VERIFY STUDY OF RUSFERTIDE IN PATIENTS WITH POLYCYTHEMIA VERA PROTAGONIST THERAP...
2025-03-03 20:19
